Compugen Ltd. (NASDAQ:CGEN) Q3 2021 Earnings Conference Call November 12, 2021 ET Company Participants Anat Cohen-Dayag – President and CEO Yvonne Naughton – Head of Investor Relations and Corporate Communications Henry Adewoye – Chief Medical Officer Ari Krashin – Chief Financial and Operating Officer Eran Ophir – Vice President Research & Drug Discovery Conference Call Participants Mark Breidenbach – Oppenheimer Stephen Willey – Stifel Daina Graybosch – SVB Chris Howerton – Jefferies Tony Butler – ROTH Ca ...

Financial Data and Key Metrics Changes - Research and development expenses for Q2 2021 were $6.8 million, an increase from $4.4 million in Q2 2020, reflecting the expansion of clinical trials [41] - Net loss for Q2 2021 was $9.5 million or $0.11 per share, compared to a net loss of $6.2 million or $0.08 per share in Q2 2020 [42] - As of June 30, 2021, the company had approximately $111 million in cash, down from approximately $119 million as of March 31, 2021, with no debt [42] Business Line Data and Key Metrics Changes - The company is focused on the DNAM axis, specifically targeting PVRIG, TIGIT, and PD-1 pathways, with ongoing clinical studies evaluating these pathways [6][11] - COM701, the first-in-class anti-PVRIG antibody, is being evaluated in monotherapy and combination studies, showing promising preliminary data [12][14] - COM701 in combination with nivolumab resulted in a disease control rate of 67%, with notable responses in tumor types typically unresponsive to immune checkpoint inhibitors [13] Market Data and Key Metrics Changes - The company is the only one targeting PVRIG in a clinical setting, maintaining a first-mover advantage in the DNAM axis [11][28] - There is growing interest in the dual and triple blockade of DNAM axis members, indicating a competitive landscape in immuno-oncology [28][29] Company Strategy and Development Direction - The company aims to maintain its first-mover advantage by executing a comprehensive clinical program with innovative combination therapies [17][34] - The strategy includes a biomarker-informed clinical program to evaluate different combinations of PVRIG, TIGIT, and PD-1 across various tumor types [10][21] - The company is considering adding inflamed indications to its studies to assess the full blockade of the DNAM axis [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of COM701 and COM902 to expand the reach of immunotherapy to patients unresponsive to current treatments [39] - The company plans to continue executing its clinical strategy with several milestones expected in the second half of 2021, including data from ongoing studies [32][34] Other Important Information - The company has a collaboration with Bayer for the development of ILDR2, with enrollment accelerating in the Phase 1 cohort expansion study [37][38] - The company is actively pursuing biomarker identification to correlate expression levels with clinical responses [22][66] Q&A Session Summary Question: What is the potential of TCF7 as a biomarker for patients? - Management indicated that TCF7 may be a challenging biomarker to monitor from peripheral blood compared to tumor samples [44][46] Question: What are the expected patient numbers for upcoming readouts? - Approximately 15 to 20 patients are expected for both the triple combination and COM902 dose escalation studies [49] Question: How does the company view the activity of VISTA in relation to the DNAM axis? - Management acknowledged the importance of MIALU checkpoints and is evaluating their efficacy in combination with current pipelines [51][53] Question: What is the company's strategy regarding potential partnerships? - The company is open to collaborative arrangements while ensuring it retains control over its key assets [60][61] Question: What is the correlation between PVRL2 and PD-L1 expression? - PVRL2 can be high in both PD-L1 positive and negative tumor types, indicating its potential as a target in various cancers [92] Question: Is there a correlation between peripheral and intratumoral immune cell populations? - There is a correlation, but the company emphasizes the importance of tumor biopsies for accurate assessment [93][94]

TGOM FROM CODE TO CURE® THE TIGIT PATHWAY PVRIG, a Novel Pathway Member Ta r g e t s f o r C a n c e r I m m u n o t h e r a p y : A D e e p D i v e E r a n O p h i r, V P R e s e a r c h & D r u g D i s c o v e r y J u n e 2021 T h e D N A M-1 A x i s • DNAM-1 axis plays an essential role in tumor immunology • PVRIG binds PVRL2 as a functional ligand (TIGIT has a low affinity for PVRL2) 中 • DNAM-1 axis – two parallel dominant complementary inhibitory pathways (PVRIG & TIGIT/CD96?) • TIGIT and PVRIG deliver ...

Compugen Ltd. (NASDAQ:CGEN) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET | --- | |------------------------------------------------------------------------| | | | Company Participants | | Anat Cohen-Dayag - CEO | | Ari Krashin - CFO and COO | | Henry Adewoye - Chief Medical Officer | | Conference Call Participants | | Mark Breidenbach - Oppenheimer Stephen Willey - Stifel | | Daina Graybosch - SVB Leerink | | | | Ren Benjamin - JMP Securities Asthika Goonewardene - Truist Securities | | | | Roger ...

Financial Data and Key Metrics Changes - Revenue for Q4 and full year 2020 was $2 million, marking the first development milestone from the license agreement with AstraZeneca [86] - Research and development expenses for the full year 2020 were $22.8 million, a 15% increase from $19.8 million in 2019, with Q4 expenses at $8.1 million, an 88% increase from $4.3 million in the prior year [87] - Net loss for the full year 2020 was $29.7 million or $0.37 per share, compared to a net loss of $27.3 million or $0.43 per share in 2019 [88] - Cash and cash-related accounts as of December 31, 2020, were approximately $124 million, up from $44 million at the end of the previous year [90] Business Line Data and Key Metrics Changes - The company is executing a comprehensive clinical development program for its anti-PVRIG and TIGIT assets, focusing on the DNAM axis signaling pathways [6][28] - The combination arm of the Phase 1 study of COM701 with nivolumab showed a disease control rate of approximately 67% [10][58] - In the COM701 monotherapy cohort expansion, 30% of patients had stable disease, with a disease control rate of 47% across the study [75] Market Data and Key Metrics Changes - The company is expanding its collaboration with Bristol-Myers Squibb (BMS) to include a Phase 1b cohort expansion study evaluating COM701 with nivolumab [12][31] - The upcoming studies will target various tumor types, including ovarian, breast, endometrial, and microsatellite stable colorectal cancer [15][31] Company Strategy and Development Direction - The company aims to maintain its leadership position in the DNAM axis immunotherapy space by advancing its clinical programs and exploring combination therapies [28][29] - The strategy includes evaluating the dual blockade of PVRIG with PD1 or TIGIT and triple blockade with PD1 and TIGIT [25][81] - The company is also focusing on early-stage pipeline programs targeting the immunosuppressive tumor microenvironment [45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of PVRIG and TIGIT as new immunotherapy targets, highlighting the growing interest in these pathways within the biopharma industry [27][29] - The company remains optimistic about its clinical data and the potential for COM701 to provide meaningful clinical benefits in heavily pre-treated patient populations [78] Other Important Information - The company has received multiple patents to protect its pipeline candidates, including COM701 and COM902 [46] - The ongoing COVID-19 pandemic has not significantly impacted the company's activities, with enrollment and data collection remaining on track [51] Q&A Session Summary Question: Differences in Efficacy Between Monotherapy and Combination Arms - Management noted that the monotherapy expansion cohort's primary objective was to establish safety and tolerability, while the combination arm showed preliminary antitumor activity [94][96] Question: Insights on Complete Response at Low Dosage - Management explained that the complete response observed at a low dosage may be due to the time required for COM701 to inhibit cancer cell activity, especially in previously treated patients [101][102] Question: Biomarker Strategy for Patient Selection - The company plans to evaluate pre- and post-treatment samples to correlate biomarkers with antitumor activity, focusing on the DNAM axis [103][111] Question: Kinetics of Complete Response Patients - Management confirmed that the patient with complete response had been on study treatment for nine months before the response was observed [118] Question: Enrollment Plans for Doublet Dose Expansion Cohorts - The company plans to enroll up to 20 patients in the dual combination expansion cohorts, which will include a more significant number of patients across various tumor types compared to the monotherapy expansion [122]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________ ____________________________________ ___________________________________________________________ ________________________________________________ ________________________________________________ FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 ...

compugen CORPORATE OVERVIEW November 2020 SAFE HARBOR STATEMENT 2 This presentation contains "forward-looking statements" within the meaning of the the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," and ...

Start Time: 08:30 January 1, 0000 9:25 AM ET Â Compugen Ltd. (NASDAQ:CGEN) Q3 2020 Earnings Conference Call November 05, 2020, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO Henry Adewoye - SVP and CMO Ari Krashin - CFO and COO Eran Ophir - VP, Research and Drug Discovery Elana Holzman - Director, IR and Corporate Communications Conference Call Participants Bonnie Quach - Stifel Daina Graybosch - SVB Leerink Mark Breidenbach - Oppenheimer Allen Donne - Truist Securities Justin Walsh - ...

Compugen Ltd (NASDAQ:CGEN) Q2 2020 Earnings Conference Call July 30, 2020 8:30 AM ET Company Participants Elana Holzman - Investor Relations Anat Dayag - CEO Henry Adewoye - Chief Medical Officer Ari Krashin - CFO and COO Eran Ophir - VP Research and Drug Discovery Conference Call Participants Stephen Willey - Stifel Daina Graybosch - SVB Leerink Matthew Biegler - Oppenheimer Asthika Goonewardene - SunTrust Colin White - Jefferies Justin Walsh - JMP Securities Tony Butler - Roth Capital Operator Ladies and ...

Pipeline Highlights - Compugen has an innovative immuno-oncology portfolio with first-in-class drugs in Phase 1 clinical trials, including COM701, COM902, and BAY1905254[5] - Encouraging preliminary clinical data for COM701 shows signals of anti-tumor activity and is well-tolerated, with a disease control rate of 69% in monotherapy and 75% in combination dose escalation[5, 45, 47] - Durable responses of over six months were observed in 21% (6/28) of patients treated with COM701[5] - COM902, an anti-TIGIT therapeutic monoclonal antibody, is in Phase 1 study for patients with advanced malignancies, with initial data expected in 2021[6, 66] - BAY 1905254, an ILDR2 inhibitor being developed by Bayer, is in Phase 1 clinical development[6] Strategic Collaborations & Financial Position - Strategic collaborations with leading pharma companies like Bristol-Myers Squibb and Bayer validate Compugen's targets and approach[5, 68] - As of March 31, 2020, Compugen had a cash balance of approximately $121 million and no debt[71] - The company's market capitalization was approximately $1 billion as of May 2020[71] - Expected gross cash expenditures for 2020 are approximately $27 million[71] Platform & Vision - Compugen's computational platform is a proven engine for novel drug targets, enabling the identification of new I/O pathways and translation to clinical validation[5, 13] - The company's vision is to transform patient lives by developing first-in-class therapeutics based on its computational target discovery platform[4] - Compugen is addressing a significant unmet need, as 70-80% of patients are non-responsive to approved cancer immunotherapies[14]